Search markets
Search icon A magnifying glass. It indicates, "Click to perform a search".
Search markets
Search icon A magnifying glass. It indicates, "Click to perform a search".
Close icon Two crossed lines that form an 'X'. It indicates a way to close an interaction, or dismiss a notification.

Bristol-Myers Squibb Co. Stock , BMY

48.57 -0.72 -1.46%
03:59:59 PM BTT
Plus500. 82% of retail CFD accounts lose money
News Analyst Data Analyst Opinions Insider Activity Dividend Calendar

On Wednesday 09/11/2024 the closing price of the Bristol-Myers Squibb Co. share was $48.57 on BTT. Compared to the opening price on Wednesday 09/11/2024 on BTT of $49.12, this is a drop of 1.13%. Bristol-Myers Squibb Co.'s market capitalization is $83.26 B by 2.03 B shares outstanding.
Is Bristol-Myers Squibb stock a Buy, Sell or Hold? Bristol-Myers Squibb stock has received a consensus rating of hold. The average rating score is and is based on 17 buy ratings, 23 hold ratings, and 9 sell ratings.
What was the 52-week low for Bristol-Myers Squibb stock? The low in the last 52 weeks of Bristol-Myers Squibb stock was 39.36. According to the current price, Bristol-Myers Squibb is 123.42% away from the 52-week low.
What was the 52-week high for Bristol-Myers Squibb stock? The high in the last 52 weeks of Bristol-Myers Squibb stock was 61.01. According to the current price, Bristol-Myers Squibb is 79.61% away from the 52-week high.
What are analysts forecasts for Bristol-Myers Squibb stock? The 49 analysts offering price forecasts for Bristol-Myers Squibb have a median target of 65.51, with a high estimate of 95.00 and a low estimate of 41.00. The median estimate represents a 74.14 difference from the last price of 48.57.

Bristol-Myers Squibb Stock Snapshot

48.56
Bid
310.00
Bid Size
48.58
Ask
27.00
Ask Size
9/11/2024
Date
3:59 PM
Time
297,211.00
Volume
49.29
Prev. Close
49.12
Open
98.37 B
Market Cap in USD
2.03 B
Number of Shares
48.25
Day Low
49.27
Day High
48.57
39.36
52 Week Low
61.01
52 Week High
48.57
2.31
Dividend in USD
4.50
Dividend Yield
13.29
P/E Ratio
99.92
Free Float in %
3.88
EPS in USD
14.56
Book Value per Share in USD
6.67
Cash Flow per Share in USD
Start Trading Futures

Historical Prices for Bristol-Myers Squibb

Loading..
Date Open Close Daily High Daily Low
Price change over selected period: 0% 0

Bristol-Myers Squibb Analyst Data

Total Analysts: 49
Buy Ratings: 17 Neutral Ratings: 23 Sell Ratings: 9
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 41.00 Median: 65.51 Highest: 95.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.

Bristol-Myers Squibb Analyst Opinions

  • All
  • Buy
  • Hold
  • Sell
Date Analyst Rating Price
07/29/24 Barclays Capital
Downgraded to Sell $41
07/23/24 Deutsche Bank
Maintained Hold $45
07/22/24 Cantor Fitzgerald
Maintained Hold $45
07/10/24 Barclays Capital
Maintained Hold $41
04/26/24 BMO Capital Markets
Maintained Buy $48
04/26/24 Barclays Capital
Maintained Hold $43
04/18/24 Wells Fargo & Co
Maintained Hold $52
02/06/24 Wells Fargo & Co
Maintained Hold $51
01/03/24 Bank of America Merrill Lynch
Downgraded to Hold $60
12/27/23 Bank of America Merrill Lynch
Maintained Buy $68
11/15/23 Cantor Fitzgerald
Downgraded to Hold $55
11/09/23 Deutsche Bank
Maintained Hold $55
11/02/23 Daiwa Securities
Downgraded to Hold $54
10/30/23 Goldman Sachs
Maintained Buy $69
10/27/23 Morgan Stanley
Maintained Sell $50
10/27/23 Barclays Capital
Maintained Hold $51
10/27/23 BMO Capital Markets
Downgraded to Buy $60
10/27/23 William Blair
Downgraded to Hold
10/27/23 HSBC
Upgraded to Sell $53
10/20/23 UBS
Maintained Hold $60
10/11/23 Morgan Stanley
Maintained Sell $56
10/09/23 Cantor Fitzgerald
Maintained Buy $75
09/15/23 Cantor Fitzgerald
Maintained Buy $75
07/28/23 Wells Fargo & Co
Maintained Hold $65
07/28/23 BMO Capital Markets
Maintained Buy $79
07/28/23 Bank of America Merrill Lynch
Maintained Buy $80
07/28/23 Atlantic Equities
Maintained Buy $85
07/28/23 Barclays Capital
Maintained Hold $62
07/20/23 Cantor Fitzgerald
Maintained Buy $85
07/19/23 Morgan Stanley
Maintained Sell $59
07/14/23 HSBC
Maintained Sell $56
07/11/23 Morgan Stanley
Maintained Sell $59
07/11/23 Barclays Capital
Maintained Hold $64
07/10/23 SVB Leerink
Maintained Hold $66
05/01/23 Barclays Capital
Maintained Hold $65
04/28/23 Credit Suisse
Maintained Hold $72
04/21/23 Bank of America Merrill Lynch
Maintained Buy $85
03/06/23 Jefferies & Company Inc.
Maintained Hold $62
02/03/23 Morgan Stanley
Maintained Sell $62
02/03/23 Atlantic Equities
Maintained Buy $90
01/17/23 Cantor Fitzgerald
Maintained Buy $95
01/03/23 Wells Fargo & Co
Maintained Hold $78
11/18/22 Credit Suisse
Maintained Hold $78
11/10/22 Atlantic Equities
Maintained Buy $88
10/27/22 Morgan Stanley
Maintained Sell $60
10/27/22 Atlantic Equities
Maintained Buy $85
10/12/22 Barclays Capital
Maintained Hold $66
10/10/22 Guggenheim
Downgraded to Hold
09/14/22 Berenberg
Downgraded to Hold $76
09/12/22 BMO Capital Markets
Maintained Buy $94

Bristol-Myers Squibb Estimates* in USD

  2024 2025 2026 2027 2028
Revenue 46,749 46,611 44,119 44,720 41,551
Dividend 2.39 2.52 2.58 2.71 2.09
Dividend Yield (in %) 4.93 % 5.20 % 5.31 % 5.58 % 4.31 %
EPS 0.75 6.96 6.31 6.39 6.03
P/E Ratio 64.94 6.97 7.69 7.59 8.04
EBIT 4,569 16,809 15,346 15,986 15,363
EBITDA 5,585 20,322 18,234 20,157 19,722
Net Profit 1,491 13,944 12,483 12,700 12,022
Net Profit Adjusted 1,491 13,944 12,483 12,700 12,022
Pre-Tax Profit 4,478 17,134 15,287 15,496 14,584
Pre-Tax Profit Reported -9,080 12,225 11,786 11,282 10,391
EPS (Non-GAAP) ex. SOE 0.75 6.96 6.31 6.39 6.03
EPS (GAAP) -2.97 5.71 5.27 5.40 4.98
Gross Income 34,923 34,555 32,954 33,825 32,788
Cash Flow from Investing -1,254 -1,477 -1,462 -1,558 -1,434
Cash Flow from Operations 11,062 15,040 13,116 12,829 13,499
Cash Flow from Financing -2,722 -7,222 -6,656 -6,369 -6,485
Cash Flow per Share 8.85 7.66 6.89 6.28 4.80
Free Cash Flow 14,747 14,324 12,842 11,143 11,334
Free Cash Flow per Share 8.06 5.54 5.62 - -
Book Value per Share 10.67 12.55 14.06 12.63 13.02
Net Debt 38,014 30,679 24,775 24,679 25,158
Research & Development Exp. 9,494 9,507 9,406 9,406 9,091
Capital Expenditure 1,185 1,193 1,158 1,135 1,159
Selling, General & Admin. Exp. 8,072 8,061 7,946 7,803 7,398
Shareholder’s Equity 21,478 25,199 28,577 31,889 34,528
Total Assets 98,228 100,184 101,058 99,554 104,466
  Previous Quarter
ending 06/30/24 		Current Quarter
ending 09/30/24 		Next Quarter
ending 12/31/24 		Current Year
ending 12/31/24 		Next Year
ending 12/31/25
Earnings Estimates
No. of Analysts - 18 18 24 24
Average Estimate - 1.591 USD 1.502 USD 0.747 USD 6.962 USD
Year Ago - 0.937 USD 0.869 USD 3.879 USD -
Publish Date - 10/31/2024 2/6/2025 - -
Revenue Estimates
No. of Analysts - 17 17 22 22
Average Estimate - 11,291 USD 11,475 USD 46,749 USD 46,611 USD
Year Ago - 10,966 USD 11,477 USD 45,006 USD -
Publish Date - 10/31/2024 2/6/2025 - -
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Income Statements in Mio. USD

2023 2022 2021 2020 2019 2018 2017
Sales 45,006.00 46,159.00 46,385.00 42,518.00 26,145.00 22,561.00 20,776.00
Change of sales in % -2.50 -0.49 9.09 62.62 15.89 8.59 6.94
Gross profit on sales 25,357.00 26,490.00 26,761.00 21,700.00 17,250.00 16,075.00 15,087.00
Gross profit on sales change in % -4.28 -1.01 23.32 25.80 7.31 6.55 4.08
Operating income 8,472.00 9,271.00 9,540.00 4,492.00 6,439.00 6,394.00 5,578.00
Operating income change in % -8.62 -2.82 112.38 -30.24 0.70 14.63 7.70
Income before tax 8,440.00 7,713.00 8,098.00 -6,871.00 4,975.00 5,968.00 5,131.00
Income before tax change in % 9.43 -4.75 - - -16.64 16.31 -13.25
Income after tax 8,025.00 6,327.00 6,994.00 -9,015.00 3,439.00 4,920.00 1,007.00
Income after tax change in % 26.84 -9.54 - - -30.10 388.58 -77.41

Balance Sheet in Mio. USD

2023 2022 2021 2020 2019 2018 2017
Total liabilities 65,674.00 65,702.00 73,308.00 80,599.00 78,246.00 20,859.00 21,704.00
Long-term liabilities per share 21.48 20.88 23.64 27.41 26.90 6.28 7.43
Equity 29,485.00 31,118.00 36,006.00 37,882.00 51,698.00 14,127.00 11,847.00
Equity change in % -5.25 -13.59 -4.96 -26.70 267.74 19.50 -27.42
Balance sheet total 95,159.00 96,820.00 109,314.00 118,481.00 129,944.00 34,986.00 33,551.00
Balance sheet total change in % -1.72 -11.43 -7.74 -8.82 271.42 4.28 -0.46

Key Data in USD

2023 2022 2021 2020 2019 2018 2017
Sales per share 21.66 21.51 20.66 18.83 15.27 13.78 12.58
P/E ratio (year end quote, basic EPS) 13.29 24.40 20.01 - 31.95 17.30 100.53
P/E ratio (year end quote, diluted EPS) 13.29 24.40 20.01 - 31.95 17.30 100.53
P/E ratio (year end quote) 13.29 24.40 20.01 - 31.95 17.30 100.53
Dividend yield in % 4.50 3.04 3.22 2.97 2.62 3.10 2.56
Equity ratio in % 30.93 32.08 32.88 31.92 39.71 40.10 34.99
Debt ratio in % 69.02 67.86 67.06 68.03 60.22 59.62 64.69

Bristol-Myers Squibb Insider Activity

Name Date shares traded shares held Price type (sell/buy) option
Gallman Cari 07/31/2024 384.00 2,109.00 48.17 Sell No
Gallman Cari 07/31/2024 1,061.00 2,493.00 n/a Buy No
Caforio Giovanni 03/09/2024 47,651.00 432,266.33 53.79 Sell No
Caforio Giovanni 03/09/2024 49,745.00 479,917.33 n/a Sell No
Caforio Giovanni 03/09/2024 10,084.00 386,758.33 53.79 Sell No
Caforio Giovanni 03/09/2024 4,104.00 396,842.33 n/a Sell No
Caforio Giovanni 03/09/2024 10,088.00 377,129.33 53.79 Sell No
Caforio Giovanni 03/09/2024 3,687.00 387,217.33 n/a Sell No
Hoch Lynelle 03/09/2024 917.00 1,726.00 53.79 Sell No
Hoch Lynelle 03/09/2024 1,138.00 2,643.00 n/a Sell No
Hoch Lynelle 03/09/2024 194.00 513.00 53.79 Sell No
Hoch Lynelle 03/09/2024 94.00 707.00 n/a Sell No
Hoch Lynelle 03/09/2024 197.00 257.00 53.79 Sell No
Hoch Lynelle 03/09/2024 85.00 454.00 n/a Sell No
Plenge Robert M 03/09/2024 1,436.00 11,315.00 53.79 Sell No
Plenge Robert M 03/09/2024 2,431.00 12,751.00 n/a Sell No
Plenge Robert M 03/09/2024 283.00 8,197.00 53.79 Sell No
Plenge Robert M 03/09/2024 201.00 8,480.00 n/a Sell No
Plenge Robert M 03/09/2024 246.00 7,517.00 53.79 Sell No
Plenge Robert M 03/09/2024 157.00 7,763.00 n/a Sell No
Lenkowsky Adam 03/09/2024 3,235.00 6,650.00 53.79 Sell No
Lenkowsky Adam 03/09/2024 3,974.00 9,885.00 n/a Sell No
Lenkowsky Adam 03/09/2024 570.00 2,443.00 53.79 Sell No
Lenkowsky Adam 03/09/2024 328.00 3,013.00 n/a Sell No
Lenkowsky Adam 03/09/2024 518.00 1,439.00 53.79 Sell No

Bristol-Myers Squibb Dividend Calendar

Date Name Dividend *yield Currency
2023 Bristol-Myers Squibb Co. 2.31 4.50 USD
2022 Bristol-Myers Squibb Co. 2.19 3.04 USD
2021 Bristol-Myers Squibb Co. 2.01 3.22 USD
2020 Bristol-Myers Squibb Co. 1.84 2.97 USD
2019 Bristol-Myers Squibb Co. 1.68 2.62 USD
2018 Bristol-Myers Squibb Co. 1.61 3.10 USD
2017 Bristol-Myers Squibb Co. 1.57 2.56 USD
2016 Bristol-Myers Squibb Co. 1.53 2.62 USD
2015 Bristol-Myers Squibb Co. 1.49 2.17 USD
2014 Bristol-Myers Squibb Co. 1.45 2.46 USD
2013 Bristol-Myers Squibb Co. 1.41 2.65 USD
2012 Bristol-Myers Squibb Co. 1.37 4.20 USD
2011 Bristol-Myers Squibb Co. 1.33 3.77 USD
2010 Bristol-Myers Squibb Co. 1.29 4.87 USD
2009 Bristol-Myers Squibb Co. 1.25 4.95 USD
2008 Bristol-Myers Squibb Co. 1.24 5.33 USD
2007 Bristol-Myers Squibb Co. 1.15 4.34 USD
2006 Bristol-Myers Squibb Co. 1.12 4.26 USD
2005 Bristol-Myers Squibb Co. 1.12 4.87 USD
2004 Bristol-Myers Squibb Co. 1.12 4.37 USD
2003 Bristol-Myers Squibb Co. 1.12 3.92 USD
2002 Bristol-Myers Squibb Co. 1.12 4.84 USD
2001 Bristol-Myers Squibb Co. 1.10 2.16 USD
2000 Bristol-Myers Squibb Co. 0.98 1.33 USD
1999 Bristol-Myers Squibb Co. 0.86 1.34 USD
*Yield of the Respective Date

Bristol-Myers Squibb Calendar

Event Estimate Info Date
Earnings Report 1.591 USD Q3 2024 Earnings Release 10/31/2024
Earnings Report 1.502 USD Q4 2024 Earnings Release 02/06/2025
Earnings Report 1.891 USD Q1 2025 Earnings Release 04/24/2025
Earnings Report 2.002 USD Q2 2025 Earnings Release 07/31/2025
Earnings Report 1.833 USD Q3 2025 Earnings Release 10/30/2025
Earnings Report 1.800 USD Q4 2025 Earnings Release 01/29/2026
Earnings Report - Q1 2026 Earnings Release 04/23/2026
Earnings Report - Q2 2026 Earnings Release 07/23/2026
Earnings Report - Q3 2026 Earnings Release 10/29/2026

Bristol-Myers Squibb Past Events

Event Actual EPS Info Date
Earnings Report 0.829 USD Q2 2024 Earnings Release 07/26/2024

Bristol-Myers Squibb Profile

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Moody’s Daily Credit Risk Score

Risk
  • Low
  • Medium
  • High
4
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.

Bristol-Myers Squibb Shareholder

Owner in %
Freefloat 99.92
The Vanguard Group, Inc. 9.77
Vanguard Group, Inc. (Subfiler) 8.75
State Street Corp. 4.51
Vanguard Total Stock Market ETF 3.16
BlackRock Fund Advisors 2.93
Charles Schwab Investment Management, Inc. 2.91
Capital Research & Management Co. (International Investors) 2.73
Vanguard 500 Index Fund 2.59
JPMorgan Investment Management, Inc. 2.37
Schwab US Dividend Equity ETF 2.37
BlackRock Institutional Trust Co. NA 2.25
Geode Capital Management LLC 2.08
Norges Bank (13F) 1.61
Government Pension Fund - Global (The) 1.48
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.

Bristol-Myers Squibb Management

Name Job
Zack Newman Associate Director-Global Sustainability Strategy
Christopher S. Boerner Chairman & Chief Executive Officer
Adam Lenkowsky Chief Commercialization Officer & Executive VP
Kimberly McCutcheon Jablonski Chief Compliance & Ethics Officer
Greg Meyers Chief Digital & Technology Officer
David V. Elkins Chief Financial Officer & Executive Vice President
Amanda Poole Chief Human Resources Officer & Executive VP
Samit Hirawat Chief Medical Officer & EVP-Drug Development
Catalina Vargas Chief Of Staff
Melissa Seymour Chief Quality Officer
Robert M. Plenge Chief Research Officer, Head-Research & EVP
William Perhacs Director-Global Energy & Sustainability Services
Frank Incontrera Director-Global Energy Services
Sandra Leung Executive Vice President & General Counsel
Cari Gallman Executive Vice President-Corporate Affairs
Cynthia Piccirillo Group Director
Krisztina Nemenyi Head-Asia Pacific Global Regulatory Affairs
Laura Hortas Head-Corporate & Employee Communications
Deepak L. Bhatt Independent Director
Derica W. Rice Independent Director
Julia A. Haller Independent Director
Karen H. Vousden Independent Director
Manuel Hidalgo Medina Independent Director
Michael R. McMullen Independent Director
Paula A. Price Independent Director
Peter J. Arduini Independent Director
Phyllis R. Yale Independent Director
Theodore Rapp Samuels Lead Independent Director
Abed Al-Nasser Odeh Manager
Louis S. Schmukler President-Global Product Development & Supply
Amy Fallone Secretary
Estelle Vester-Blokland Senior VP-Global Medical Affairs
Teresa M. Foy Senior VP-Immuno Oncology & Cell Therapy
Mark Rolfe Senior Vice President
Phil Holzer Senior Vice President & Controller
Monica Shaw Senior Vice President-Major Markets
MARIA V LOPEZ BRESNAHAN Vice President